Pathak Soumitra, Le Nguyen Bui Thao, Oyama Taiji, Odahara Yusuke, Momotake Atsuya, Ikebukuro Kazunori, Kataoka-Hamai Chiho, Yoshikawa Chiaki, Kawakami Kohsaku, Kaizuka Yoshihisa, Yamazaki Tomohiko
Research Center for Macromolecules and Biomaterials, National Institute for Materials Science (NIMS), 1-2-1 Sengen, Tsukuba 305-0047, Japan.
Graduate School of Life Science, Hokkaido University, Kita 10, Nishi 8, Sapporo 060-0808, Japan.
Biomolecules. 2025 Jan 10;15(1):95. doi: 10.3390/biom15010095.
Synthetic cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODNs) are promising candidates for vaccine adjuvants, because they activate immune responses through the Toll-like receptor 9 (TLR9) pathway. However, unmodified CpG ODNs are quickly degraded by serum nucleases, and their negative charge hinders cellular uptake, limiting their clinical application. Our group previously reported that guanine-quadruplex (G4)-forming CpG ODNs exhibit enhanced stability and cellular uptake. G4 structures can form in parallel, anti-parallel, or hybrid topologies, depending on strand orientation, but the effects of these topologies on CpG ODNs have not yet been explored. In this study, we designed three distinct G4 topologies as scaffolds for CpG ODNs. Among the three topology, the parallel G4 CpG ODN demonstrated the highest serum stability and cellular uptake, resulting in the strongest immune response from macrophage cells. Additionally, we investigated the binding affinities of the different G4 topologies to macrophage scavenger receptor-1 and TLR9, both of which are key to immune activation. These findings provide valuable insights into the development of CpG ODN-based vaccine adjuvants.
合成的胞嘧啶-磷酸-鸟嘌呤寡脱氧核苷酸(CpG ODNs)是很有前景的疫苗佐剂候选物,因为它们通过Toll样受体9(TLR9)途径激活免疫反应。然而,未修饰的CpG ODNs会被血清核酸酶迅速降解,并且它们的负电荷会阻碍细胞摄取,限制了它们的临床应用。我们小组之前报道过,形成鸟嘌呤四链体(G4)的CpG ODNs表现出更高的稳定性和细胞摄取能力。G4结构可以根据链的方向以平行、反平行或混合拓扑结构形成,但这些拓扑结构对CpG ODNs的影响尚未得到探索。在本研究中,我们设计了三种不同的G4拓扑结构作为CpG ODNs的支架。在这三种拓扑结构中,平行G4 CpG ODN表现出最高的血清稳定性和细胞摄取能力,从而在巨噬细胞中引发最强的免疫反应。此外,我们研究了不同G4拓扑结构与巨噬细胞清道夫受体-1和TLR9的结合亲和力,这两者都是免疫激活的关键。这些发现为基于CpG ODN的疫苗佐剂的开发提供了有价值的见解。